Open-acess adjuvants and vaccine formulations for Global Health
VFI is incorporated in The Republic and canton of Geneva, Switzerland, as a not-for-profit company.
History
Adjuvants have been added to vaccines to enhance the immune response to vaccine antigens for more than a century, with the discovery of aluminium salts as a beneficial component for vaccines. However, most of the know-how around the research, development and use of adjuvants is still not readily available to the vaccine community.
This led to the creation of the Vaccine Formulation Laboratory (VFL) initially at the University of Lausanne in 2010, supported by the World Health Organization. After its externalization from the University, VFI established itself as an independent, not-for-profit company in Switzerland.
VFI’s mission is to provide adjuvants, research on adjuvants, preclinical development of adjuvanted vaccines, technology transfer and training, to the entire vaccine community, with a focus to low- and middle-income countries. VFI’s team works across several sites including two state-of-the art laboratories in Geneva and Lausanne (Switzerland).
Not-for-profit status
In light of its not-for-profit mission and activities VFI has been recognized of public utility and granted tax exemption ruling from the Tax Authorities of the Republic and Canton of Geneva.
VFI is also certified equivalent to a U.S. public charity pursuant to U.S. IRC § 501(c)(3).
Activities
VFI provides a range adjuvants, technology, and expertise for the optimisation of vaccines in research and development. With its adjuvant SWE, SQ, LQ, LMQ, VFI is offering additional tools to increase the efficiency of vaccines.
VFI assists with and supplies adjuvants for research and clinical development
VFI optimises and characterises adjuvanted vaccine formulations
VFI supports manufacturing and quality control technology transfer
VFI conducts training in adjuvants and vaccine formulations
VFI assists with and supplies adjuvants for research and preclinical development
VFI optimises and characterises adjuvanted vaccine formulations
VFI supports manufacturing and quality control technology transfer